[Effects of ursodeoxycholic acid in patients with cholestasis of pregnancy].
In an open, pilot study, the efficacy and safety of ursodeoxycholic acid (UDCA) in the treatment of intrahepatic cholestasis of pregnancy was investigated. Four patients received 1 g/day of UDCA during 20 days and another 2 patients received 2 identical periods of treatment separated by a 14-day interval free of drug. Pruritus and serum levels of total bile salts and glutamic-pyruvic transaminase improved significantly during treatment with UDCA. Although pruritus and the laboratory alterations had a relapse in the second week after UDCA was discontinued, they improved again in the 2 patients who received a second treatment with UDCA. No adverse reactions were detected in the mothers or in their babies. All newborns are thriving normally, in a follow-up that lasted 3 to 6 months after delivery. It is concluded that UDCA appears to be safe when administered in late pregnancy; its promising efficacy in the treatment of intrahepatic cholestasis of pregnancy should now be confirmed in controlled clinical trials.
Palma
J
J
Departamento de Preclínicas, Facultad de Medicina, Universidad de Chile (División Oriente).
Reyes
H
H
Ribalta
J
J
Iglesias
J
J
González
M
M
Hernández
I
I
Alvarez
C
C
Molina
C
C
Danitz
A M
AM
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001647:Bile Acids and Salts / Q000097:blood; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D010865:Pilot Projects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D001647:Bile Acids and Salts; D014580:Ursodeoxycholic Acid; D000410:Alanine Transaminase
Efectos del ácido ursodeoxicólico en pacientes con colestasis gravídica.